Aura Biosciences, Inc. (AURA) NASDAQ
6.90
-0.29(-4.03%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Aura Biosciences, Inc.
Address
85 Bolton Street
Boston, MA 02140
United States of America (the)
Phone
617 500 8864
Sector
Healthcare
Industry
Biotechnology
Employees
106
First IPO Date
October 29, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Elisabet de los Pinos | Founder, Chief Executive Officer, President & Director | 950,496 | 1974 |
| Natalie C. Holles | President, CEO & Director | 0 | 1973 |
| Anthony S. Gibney | Chief Financial & Business Officer | 604,091 | 1971 |
| Conor Kilroy | Chief Legal Officer & Secretary | 611,162 | 1982 |
| Jill Hopkins | Chief Medical Officer & President of Research and Development | 792,750 | 1965 |
| Anthony Daniels | Vice President & Therapeutic Area of Head Ocular Oncology | 0 | N/A |
| Mark Plavsic | Chief Technology Officer | 0 | 1961 |
| Sabine Brookman-May | Senior Vice President & Therapeutic Area Head of Urologic Oncology | 0 | N/A |
| Joe McQuaid | VP & Therapeutic Area Head of Urologic Oncology | 0 | N/A |
| Patrick Nealon | Senior Vice President of Clinical Development Operations | 0 | N/A |
| Amy Elazzouzi | Interim Principal Accounting Officer, Senior Vice President of Finance & Treasurer | 0 | 1974 |
Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
